FINHUB Insights

VRTX · Q3 FY25 · Jul 1 – Sep 30, 2025

Vertex Pharmaceuticals Q3 FY25: where the revenue came from and where it went

Vertex Pharmaceuticals Q3 FY25: revenue $3.1B (+11% year over year). Net profit $1.1B. Largest cohort TRIKAFTAKAFTRIO $2.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 4, 2025 10-Q
Sankey diagram of Vertex Pharmaceuticals's income statement for Q3 FY25: revenue of $3.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.1B +11% year over year
Gross profit$2.7B 87% margin
Operating profit$1.2B 39% margin
Net profit$1.1B 35% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.1 100% +11%
TRIKAFTAKAFTRIO 2.7 87% +3%
ALYFTREK 0.2 6%
Manufactured Product Other 0.2 6% −6%
Cost of revenue−0.413%
Gross profit2.787% margin+1pp
SG&A−0.414%+1pp
Other−1.133%+0pp
Operating profit1.239% margin−2pp
Tax−0.2
Net profit1.135%−3pp
Filing on EDGAR More quarters of VRTX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters